What Is Hemochromatosis?
Hemochromatosis is a genetic disorder that causes your body to absorb too much iron from food. That excess iron accumulates in organs — liver, pancreas, heart, pituitary gland, and testes — where it triggers inflammation and permanent tissue damage1.
About 1 in 200 to 300 people of northern European descent carry two copies of the HFE gene mutation (C282Y) that causes hereditary hemochromatosis2. Men typically develop symptoms between ages 30 and 60. Women usually remain symptom-free until after menopause, when monthly menstrual blood loss stops providing natural iron depletion3. Iron deposits in the pituitary gland disrupt the hormonal signals that control testosterone production, leading to secondary hypogonadism — low testosterone caused by a failure in the brain's signaling system rather than testicular disease1.
Key Takeaways
Most men see testosterone recovery within 3 to 12 months of normalizing iron levels through phlebotomy. A simple genetic test (HFE mutation screening) confirms the diagnosis, and early treatment prevents irreversible organ damage.
- Reversible: Hypogonadism often resolves with consistent iron depletion
- Monitoring: Ferritin and testosterone labs every 3 months during treatment
Signs and Symptoms
Hemochromatosis produces a constellation of symptoms that reflect multi-organ iron overload. The average delay from first symptoms to diagnosis is 10 years1.
Fatigue and Weakness
Persistent exhaustion unrelated to exertion. Iron toxicity in muscle tissue and the metabolic effects of iron-damaged organs drive chronic low energy.
Low Libido and Erectile Dysfunction
Reduced sexual desire and difficulty achieving or maintaining erections. Iron deposits in the pituitary and testes disrupt testosterone production.
Joint Pain and Stiffness
Iron accumulation in joint cartilage causes arthropathy, most commonly affecting the knuckles and knees. Pain may mimic osteoarthritis.
Abdominal Pain and Cirrhosis
Upper right quadrant discomfort signals liver enlargement. Untreated iron overload progresses to cirrhosis, hepatocellular carcinoma, and liver failure.
Early disease is often asymptomatic. As iron levels rise, nonspecific fatigue and joint complaints dominate. Advanced disease manifests as cirrhosis (liver scarring), heart failure from cardiomyopathy, diabetes from pancreatic beta-cell damage, and hypogonadism from pituitary or testicular iron toxicity1.
Sexual dysfunction in hemochromatosis reflects both central and peripheral mechanisms. Iron deposition in the pituitary reduces luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, blunting testicular stimulation. Simultaneously, iron accumulates directly in testicular Leydig cells, impairing their response to LH1. The result is low testosterone from both reduced signaling and damaged testosterone-producing cells.
Approximately 50% of men with untreated hemochromatosis develop diabetes from pancreatic iron overload3. Diabetes worsens erectile dysfunction and creates a metabolic cascade where insulin resistance further suppresses testosterone. Skin hyperpigmentation (a bronze or gray discoloration) appears in advanced cases from iron and melanin deposition.
Hypogonadism is a condition of abnormally low testosterone production caused by dysfunction of the pituitary gland or testes. In hemochromatosis, iron deposits disrupt hormone signaling and damage testosterone-producing cells, resulting in reduced sexual function and energy.
Cardiomyopathy is a disease of the heart muscle that weakens its ability to pump blood effectively. In hemochromatosis, iron accumulation in cardiac tissue causes progressive damage, leading to heart failure and reduced oxygen delivery to the body.
Cirrhosis is irreversible liver scarring and fibrosis that destroys normal liver function. In hemochromatosis, chronic iron overload triggers inflammation and collagen deposition, eventually causing liver failure, portal hypertension, and increased hepatocellular carcinoma risk.
Why Iron Overload Causes Low Testosterone
Hemochromatosis disrupts testosterone production through a genetic mutation that removes the body's normal brake on iron absorption. The downstream effects damage multiple points in the hormonal control system.
HFE Gene Mutations and Hepcidin Dysfunction
The C282Y mutation on chromosome 6 prevents normal hepcidin production. Hepcidin is the master regulator of intestinal iron uptake. Without it, your gut absorbs 2-3 times more iron than needed from every meal1. Excess iron binds to transferrin in the bloodstream, then deposits as hemosiderin in parenchymal tissues when transferrin saturation exceeds 45-50%.
Pituitary Iron Deposition and HPG Axis Disruption
Iron accumulates in gonadotroph cells of the anterior pituitary, physically damaging the cells responsible for LH and FSH secretion. The hypothalamus signals normally, but the pituitary fails to respond1. Low LH means weak or absent stimulation of testicular Leydig cells, resulting in secondary hypogonadism.
Gonadal Iron Accumulation and Direct Testicular Damage
Iron deposits directly in Leydig cells, the testosterone-producing cells of the testes. Even when pituitary LH levels normalize with treatment, damaged Leydig cells may not respond fully. This creates a mixed picture where both central signaling and peripheral response are impaired.
The relationship between hemochromatosis and low testosterone is causal and bidirectional in its complications. Iron overload drives hypogonadism. Low testosterone then amplifies fatigue, reduces muscle mass, and worsens insulin resistance — all of which exacerbate the patient's functional decline1.
Pancreatic involvement adds metabolic complexity. Iron destroys insulin-producing beta cells in approximately 50% of homozygous C282Y carriers, causing diabetes mellitus3. Diabetes independently suppresses testosterone via increased aromatase activity in adipose tissue and through hypothalamic insulin resistance that blunts GnRH pulsatility. The dual hit of pituitary damage and metabolic dysfunction creates severe, treatment-resistant hypogonadism in advanced cases.
Diagnosis and Lab Tests
Diagnosis begins with iron studies in any patient presenting with unexplained fatigue, joint pain, erectile dysfunction, or elevated liver enzymes — especially men of northern European descent between ages 30 and 60.
Serum ferritin and transferrin saturation are the first-line screening tests. Ferritin above 300 ng/mL in men or 200 ng/mL in women raises suspicion1. Transferrin saturation above 45% confirms pathologic iron overload3. These thresholds distinguish hemochromatosis from normal physiologic variation or inflammation-driven ferritin elevation.
| Test | Normal Range | Hemochromatosis Finding |
|---|---|---|
| Serum Ferritin | 30-300 ng/mL (men) 15-200 ng/mL (women) |
>300 ng/mL (men) >200 ng/mL (women) |
| Transferrin Saturation | 20-50% | >45-50% |
| Serum Iron | 60-170 μg/dL | Elevated (>170 μg/dL) |
| Total Testosterone | 300-1000 ng/dL | <300 ng/dL (secondary hypogonadism) |
| LH | 1.7-8.6 mIU/mL | Low or inappropriately normal |
| FSH | 1.5-12.4 mIU/mL | Low or inappropriately normal |
Genetic testing for HFE mutations confirms the diagnosis. C282Y homozygosity is the most common genotype in hereditary hemochromatosis. Compound heterozygosity (C282Y/H63D) causes milder disease1. Genetic confirmation is particularly useful in younger patients or those with borderline iron studies, as it clarifies whether lifelong monitoring is needed.
Testosterone, LH, and FSH should be checked in any male hemochromatosis patient reporting sexual dysfunction or fatigue. The pattern is secondary hypogonadism — low testosterone with low or inappropriately normal LH and FSH. Primary testicular failure (from direct iron damage) would show high LH and FSH. Many patients have a mixed picture.
Liver imaging (ultrasound or MRI) and liver function tests (ALT, AST, bilirubin) assess hepatic iron deposition and fibrosis. Fasting glucose and HbA1c screen for diabetes. An echocardiogram evaluates for iron cardiomyopathy in advanced cases. Liver biopsy with Perls' Prussian blue staining quantifies hepatic iron concentration, but it's rarely needed with genetic confirmation1.
Diagnostic delay averages 10 years from symptom onset. Joint pain and fatigue are often dismissed or attributed to aging. By the time cirrhosis or diabetes develops, significant irreversible organ damage has occurred1. Early detection through high-risk population screening prevents morbidity.
Differential Diagnosis
Secondary iron overload from chronic transfusions, chronic liver disease, or alcoholic cirrhosis can mimic hemochromatosis. Genetic testing distinguishes hereditary from acquired causes.
For hypogonadism, consider obesity-related testosterone suppression, obstructive sleep apnea, prolactinoma, Klinefelter syndrome, or medication-induced hypogonadism (opioids, glucocorticoids). Low LH and FSH narrow the differential to secondary causes — hemochromatosis, pituitary adenoma, hyperprolactinemia, or chronic illness.
Treatment and Management
Phlebotomy (First-Line Iron Depletion)
Weekly removal of 500 mL of blood until ferritin drops below 50 ng/mL, then maintenance phlebotomy every 2-3 months. This is the gold standard treatment and reverses many symptoms1.
Chelation Therapy
Iron chelators like deferasirox are second-line for patients who cannot tolerate phlebotomy (severe anemia, poor venous access, cardiac contraindications). Less effective than phlebotomy for most patients.
Dietary Iron Restriction
Avoid iron-fortified cereals, red meat, and iron supplements. Do not take vitamin C with meals, as it enhances iron absorption. Limit alcohol — it increases iron uptake and accelerates liver damage.
Liver Monitoring
Annual ultrasound or FibroScan to assess fibrosis progression. Patients with established cirrhosis need hepatocellular carcinoma surveillance every 6 months with ultrasound and alpha-fetoprotein4.
Regular Exercise
Resistance training and aerobic activity improve insulin sensitivity and may modestly support testosterone production. Exercise does not deplete iron but counters metabolic complications.
Testosterone Replacement Therapy
TRT is reserved for persistent secondary hypogonadism after iron depletion. Start only after ferritin normalizes and symptoms fail to resolve with phlebotomy alone. Monitor for polycythemia and ferritin rebound.
Reversibility of Hypogonadism
Testosterone levels often recover spontaneously with iron depletion. Case reports document normalization of libido, erectile function, and testosterone production within 3 to 12 months of achieving target ferritin levels1. The pituitary appears more resilient than the testes — LH and FSH secretion typically improves faster than testicular testosterone synthesis.
Monitor total testosterone, free testosterone, LH, and FSH every 3 months during the iron depletion phase. Continue monitoring for 6 to 12 months after ferritin stabilizes below 50 ng/mL. If testosterone remains suppressed despite normalized iron stores, evaluate for irreversible testicular damage or other causes of hypogonadism.
Patients with longstanding, untreated hemochromatosis may have permanent Leydig cell fibrosis. These men show persistently low testosterone even after successful iron depletion. Testicular ultrasound and repeat hormonal assessment guide decisions about TRT.
TRT Considerations
TRT is not first-line treatment and lacks robust trial data specific to hemochromatosis. Start TRT only after confirming iron overload is controlled and symptoms persist. Testosterone therapy increases red blood cell production, which can raise hematocrit and secondarily increase total body iron stores. This creates a management challenge — phlebotomy frequency may need to increase to offset TRT-induced erythrocytosis.
Begin with conservative dosing. Testosterone cypionate 100 mg intramuscularly every week or every 10 days avoids supraphysiologic peaks. Recheck ferritin, hematocrit, and hemoglobin 6 weeks after starting TRT and every 3 months thereafter. If ferritin climbs above 100 ng/mL or hematocrit exceeds 52%, increase phlebotomy frequency or reduce testosterone dose.
Topical formulations (gels, creams) produce less erythrocytosis than injections but cost more and require daily application. Shared decision-making with your provider should weigh the erythrocytosis risk, cost, and convenience.
Treatment Timeline
Phlebotomy induction typically runs 6 to 12 months of weekly sessions, depending on starting ferritin levels. Maintenance phlebotomy continues lifelong every 2 to 3 months. Energy and joint pain often improve within weeks of starting iron depletion. Sexual function recovery lags — expect 3 to 12 months for testosterone normalization4.
Cirrhosis and diabetes are usually irreversible once established. Early diagnosis and treatment before organ damage occurs prevents these complications. Patients diagnosed before ferritin exceeds 1000 ng/mL and before cirrhosis develops have normal life expectancy with phlebotomy adherence1.
The Bottom Line
Iron depletion through phlebotomy is the definitive treatment for hemochromatosis and often restores testosterone levels without TRT. Start TRT only if hypogonadism persists 6 to 12 months after iron normalization. Work closely with a hematologist or hepatologist to balance iron control with any hormone therapy.